Vaccine Panel Argues Against Unblinding COVID-19 Vaccine Trials

FDA’s vaccine advisers disagreed with COVID-19 vaccine makers who claim they might have to unblind their placebo-controlled phase 3 trials should a vaccine become available through emergency use authorization. In siding with FDA, which has said trials should remain blinded for as long as possible even after an EUA is issued, the agency’s advisers said that limited vaccine availability coupled with targeted distribution and low vaccine confidence make it unlikely there will so much demand for an initial vaccine that...